You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / CE

The Nurse's Perspective on AE Management of Upcoming MEK Inhibitors for NF1-Associated Tumors

  • Authors: Molly Hemenway, DNP, NS, RN, CPNP; Shannon Langmead, RN, MSN, CRNP, CNRN; Roger Packer, MD
  • CME / CE Released: 6/5/2020
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 6/5/2021, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for hematology/oncology specialists, pediatricians, neurologists, nurses and physician assistants.

The goal of this activity is to increase clinicians' knowledge of the latest data on emerging MEK inhibitors in the treatment of NF1-associated tumors and their confidence in implementing a multidisciplinary approach to managing and mitigating adverse events (AEs) associated with these new therapies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Latest clinical trials investigating MEK inhibitors for the management of patients with NF1 and plexiform neurofibromas
    • Role of the multi-disciplinary team in managing NF1-associated tumors and the AEs of emerging therapies
  • Demonstrate greater confidence in their ability to
    • Recognize and mitigate AEs of emerging MEK inhibitors for NF1-associated tumors


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Molly Hemenway, DNP, MS, RN, CPNP

    Senior Instructor, Nurse Practitioner
    University of Colorado School of Medicine
    Children’s Hospital Colorado
    Aurora, Colorado
     

    Disclosures

    Disclosure: Molly Hemenway, DNP, MS, RN, CPNP, has disclosed no relevant financial relationships. 

Panelists

  • Shannon Langmead, RN, MSN, CRNP, CNRN

    Senior Nurse Practitioner and Clinic Coordinator
    Johns Hopkins Comprehensive Neurofibromatosis Center
    Baltimore, Maryland
    Participation by Ms Langmead does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System.
     

    Disclosures

    Disclosure: Shannon Langmead, RN, MSN, CRNP, CNRN, has disclosed the following relevant financial relationships: 
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP

  • Roger Packer, MD

    Senior Vice President of Neuroscience and Behavioral Medicine
    Director, Gilbert Family NF1 Institute
    Director, Brain Tumor Institute
    Children’s National Hospital
    Washington, DC

    Disclosures

    Disclosure: Roger Packer, MD, has disclosed the following relevant financial relationships: 
    Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals

APHON Course Director

  • Kristin M. Belderson, DNP, RN, NPD-BC, CPON

    Manager, Professional Development
    Children’s Hospital Colorado
    Aurora, Colorado
     

    Disclosures

    Disclosure: Kristin M. Belderson, DNP, RN, NPD-BC, CPON, has disclosed no relevant financial relationships.

Editor

  • Sara Fagerlie, PhD, CHCP

    Senior Medical Education Strategic Director, Medscape, LLC

    Disclosures

    Disclosure: Sara Fagerlie, PhD, CHCP, has disclosed no relevant financial relationships.

  • Yoji Yamaguchi, MA

    Associate Scientific Content Manager, Medscape, LLC

    Disclosures

    Disclosure: Yoji Yamaguchi, MA, has disclosed no relevant financial relationships.

CE Reviewer / Nurse Planner

  • Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 06/01/2021. PAs should only claim credit commensurate with the extent of their participation.

    Contact This Provider

    For Nurses

  • Awarded 0.75 contact hour(s) of continuing nursing education for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

    For Physician Assistants

    Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 06/01/2021. PAs should only claim credit commensurate with the extent of their participation.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / CE

The Nurse's Perspective on AE Management of Upcoming MEK Inhibitors for NF1-Associated Tumors

Authors: Molly Hemenway, DNP, NS, RN, CPNP; Shannon Langmead, RN, MSN, CRNP, CNRN; Roger Packer, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / CE Released: 6/5/2020

Valid for credit through: 6/5/2021, 11:59 PM EST

processing....

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print